Brief: Reneo Pharmaceuticals Reports Positive Results From Ren001 Long-Chain Fatty Acid Oxidation Disorders Study And Provides Additional Development Updates

Onkure Therapeutics

26/07/2022 12:55

July 26 (Reuters) - Reneo Pharmaceuticals Inc  RPHM.O :
    * RENEO PHARMACEUTICALS REPORTS POSITIVE RESULTS FROM REN001
LONG-CHAIN FATTY ACID OXIDATION DISORDERS (LC-FAOD) STUDY AND
PROVIDES ADDITIONAL DEVELOPMENT UPDATES
    * RENEO PHARMACEUTICALS INC - LC-FAOD PROGRAM TO MOVE
FORWARD INTO
NEXT STAGE OF CLINICAL DEVELOPMENT
    * RENEO - ENROLLMENT OF STRIDE STUDY IN PRIMARY
MITOCHONDRIAL
MYOPATHIES PATIENTS WITH MITOCHONDRIAL DNA DEFECTS ON TRACK TO
BE COMPLETED YEAR-END 2022
    * RENEO PHARMACEUTICALS - ALIGNMENT WITH EMA AND U.S. FDA;
SINGLE
PIVOTAL TRIAL FOR REGISTRATION OF REN001 IN PMM PATIENTS WITH
MTDNA DEFECTS
    * RENEO PHARMACEUTICALS INC - INTENDS TO PRESENT ADDITIONAL
DATA
FROM LC-FAOD STUDIES AT A MEDICAL CONFERENCE IN 2022
    * RENEO PHARMACEUTICALS INC - ANNOUNCED PLANS TO INITIATE
DEVELOPMENT OF REN001 FOR ADULT PMM PATIENTS WITH NDNA DEFECTS
    * RENEO - NEXT STEPS FOR THIRD REN001 DEVELOPMENT PROGRAM
INCLUDE
REQUESTING MEETINGS WITH U.S. & EUROPEAN AGENCIES TO DISCUSS
PLANNED PROGRAM

Source text for Eikon:  ID:nGNX2m31mV 
Further company coverage:  RPHM.O 

 ((Reuters.Briefs@thomsonreuters.com;))